A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC

• Status: Completed
• Trial end date: 2017-09-07
• Target enrollment: 0
• Participant gender: All

Summary

A Phase 2 Study with Safety Lead-in, Evaluating TAS-102 Plus Nivolumab in Participants with Microsatellite Stable Refractory Metastatic Colorectal Cancer

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Taiho Oncology, Inc.
• Treatments: Antibodies, Monoclonal; Nivolumab; Trifluridine

Criteria

Inclusion Criteria:

1. Has provided written informed consent.

2. Participants with confirmed histologically proven metastatic or locally advanced colorectal adenocarcinoma who are microsatellite stable (MSS) (ie, not microsatellite instable [MSI]) based on either an analysis of tissue from a prior biopsy or based on tissue from a new biopsy.

3. Participants with the presence of at least 1 lesion with measurable disease as defined by 10 millimeters (mm) in the longest diameter for a soft tissue lesions or 15 mm in the short axis for a lymph node by response evaluation criteria in solid tumors (RECIST) and immune related response-criteria (irRC) for a response assessment.

4. Participants has received at least 2 prior lines of standard chemotherapies for metastatic colorectal cancer (mCRC) and is refractory to or failing those chemotherapies.

5. Age greater than or equal to (>=) 18 years.

6. Eastern Cooperative Oncology Group performance status of 0 to 1

7. Life expectancy of >=4 months.

8. Has adequate organ function.

9. Women of childbearing potential must have a negative pregnancy test (urine or serum) within 7 days before starting study drugs. Is able to take medications orally.

10. Is able to take medications "orally".

Exclusion Criteria:

1. Has a serious illness or medical condition.

2. Treatment with any of the following within the specified time frame before enrollment:

1. Major surgery within the past 4 weeks (the surgical incision should be fully healed before study drug administration).

2. Any anticancer therapy within the past 3 weeks before enrollment.

3. Extended field radiation within the past 4 weeks or limited field radiation within the past 2 weeks before enrollment.

4. Any investigational drug/device received within the past 4 weeks or 5 times the half-life (whichever is shorter) before enrollment.

3. Previous treatment with TAS-102.

4. Prior treatment with anti-programmed cell death-1 (anti-PD-1), anti-programmed cell death ligand (anti-PD-L1), anti programmed cell death ligand 2, anti-CD137, anti-OX-40, anti CD40, anti cytotoxic T lymphocyte associated antigen-4 antibodies, or any other immune checkpoint inhibitors.

5. Unresolved toxicity of >=Common Terminology Criteria for Adverse Events version (CTCAE) version 4.03 grade 2 attributed to any prior therapies (excluding anemia, alopecia, skin pigmentation, and platinum induced neurotoxicity).

6. Prior events of immune-mediated pneumonitis, immune-mediated colitis, immune-mediated hepatitis, immune-mediated endocrinopathies, immune mediated nephritis and renal dysfunction, immune mediated rash, immune mediated encephalitis, and history of infusion reactions to nivolumab.

7. Known or assumed hypersensitivity to TAS-102 or nivolumab or any of its ingredients, including polysorbate 80-containing infusion.

8. Previous severe hypersensitivity reaction to treatment with another mAb.

9. Pregnant or lactating female.

10. Inappropriate for entry into this study in the judgment of the investigator.